Partner Shenzhen Inno’s government-approved TCR-T therapy R&D project lifts EUDA shares 31.92%.
On April 28, 2026, EUDA Health Holdings announced that its partner Shenzhen Inno Immune received approval under the 2025 Shenzhen Key Industry R&D Program for its “Key Technology Development of TCR-T Therapy for Solid Tumors” project. The three-year initiative (2026–2028), supervised by the Shenzhen Science and Technology Innovation Bureau, targets AI-driven TCR candidate screening, improved cell persistence, and early clinical work with institutions including Shenzhen People’s Hospital. It qualifies for potential government funding of up to ~$435,000. EUDA holds non-exclusive rights to market and distribute selected Shenzhen Inno immunotherapies to customers in Malaysia. The announcement, following recent Nasdaq MVLS noncompliance notice and a March 2026 reverse split, aligned with ongoing retail momentum and elevated volume in this low-float name, driving the sharp intraday gain on April 29.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.